Comment
doi: 10.1038/s41569-018-0133-6.
No benefit of methotrexate on the risk of cardiovascular events
Affiliations
- PMID: 30487542
- DOI: 10.1038/s41569-018-0133-6
Item in Clipboard
Comment
No benefit of methotrexate on the risk of cardiovascular events
Nat Rev Cardiol.
2019 Jan.
No abstract available
Comment on
-
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415610 Free PMC article. Clinical Trial.
Similar articles
-
Methotrexate for Prevention of Cardiovascular Events.N Engl J Med. 2019 Jun 6;380(23):2276-2277. doi: 10.1056/NEJMc1905061. N Engl J Med. 2019. PMID: 31167066 No abstract available.
-
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.Arthritis Rheum. 2006 Dec;54(12):3790-8. doi: 10.1002/art.22255. Arthritis Rheum. 2006. PMID: 17136752
-
Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?Rheumatology (Oxford). 2008 Jul;47(7):939-41. doi: 10.1093/rheumatology/ken158. Epub 2008 May 12. Rheumatology (Oxford). 2008. PMID: 18474510 No abstract available.
-
On beyond methotrexate treatment of severe juvenile rheumatoid arthritis.Clin Exp Rheumatol. 1999 Jul-Aug;17(4):499-504. Clin Exp Rheumatol. 1999. PMID: 10464566 Review. No abstract available.
-
Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?Curr Pharm Des. 2014;20(4):486-95. doi: 10.2174/13816128113199990712. Curr Pharm Des. 2014. PMID: 23565635 Review.
Cited by
-
Repurposing traditional immunomodulators to target the inflammatory burden of atherosclerosis.Int J Cardiol Heart Vasc. 2020 May 12;28:100535. doi: 10.1016/j.ijcha.2020.100535. eCollection 2020 Jun. Int J Cardiol Heart Vasc. 2020. PMID: 32399483 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
